Phylogica Limited : NAOS Increases Shareholding
02/01/2012 | 08:30pm
The Company Announcements Platform
ASX Ltd
Sydney NSW 2000
January 03, 2012
PHYLOGICA: NAOS ASSET MANAGEMENT INCREASES ITS SHAREHOLDING
TO 11.5%
PERTH, AUSTRALIA: February 2, 2012 - Phylogica Ltd (ASX: PYC,
XETRA: PH7), a leading Australian peptide drug discovery
company, announced today that NAOS Asset Management has
increased its shareholding to 51,492,121 shares (representing
11.5% of Phylogica's issued share capital). This is an
increase of
10,155,739 shares from NAOS's previous reported holding in
June 2011. The shares are held by Citicorp Nominees Pty Ltd.
NAOS Asset Management is an award winning boutique investment
firm that specialises in investing in undervalued smaller
companies through the NAOS Emerging Companies Long Short
Equities Fund. The Fund was named the best performing hedge
fund in the Asia Pacific Region for 2009 by Bloomberg and is
a preeminent investment fund in the Australian Life Science
industry.
-ends-
For further information, please contact:
Nick Woolf
CFO & VP, Corporate Development Tel: +61 417 986 005 nwoolf@phylogica.com
Rudi Michelson
Monsoon Communications
Tel + 61 3 9620 3333
About Phylogica
Phylogica Limited (ASX: PYC) is a biotechnology company based
in Perth, Australia, and Oxford, UK, with a world-class drug
discovery platform harnessing the rich biodiversity of nature
to discover novel peptide therapeutics. The Company was
incorporated in 2001 as a spin out from the Telethon
Institute for Child Health Research (Perth, Australia) and
the Fox Chase Cancer Centre (Philadelphia, USA). The
Company's drug discovery
platform is based on its proprietary Phylomer®
libraries of natural peptides, which have been optimised by
evolutionary selection to have stable drug-like structures.
Phylogica offers fully integrated drug discovery services to
the pharmaceutical industry utilising its
Phylomer® libraries and proprietary screening
technologies. Its current partners include
Roche, MedImmune (AstraZeneca), Pfizer and Janssen Biotech
(Johnson & Johnson).
PO Box 8207, Subiaco East, Western Australia 6008
Tel: +61 8 9384 3284 Fax: +61 8 9284 3801
www.phylogica.com
ABN 48 098 391 961
